108 related articles for article (PubMed ID: 38840935)
1. GLP-1 RA for cardiometabolic risk reduction in obesity - How do we best describe benefit and value?
Kumar S; Blaha MJ
Am J Prev Cardiol; 2024 Jun; 18():100682. PubMed ID: 38840935
[TBL] [Abstract][Full Text] [Related]
2. Potential Roles of Glucagon-Like Peptide 1 Receptor Agonists (GLP-1 RAs) in Nondiabetic Populations.
Xu D; Nair A; Sigston C; Ho C; Li J; Yang D; Liao X; Chen W; Kuang M; Li Y; Reid C; Xiao H
Cardiovasc Ther; 2022; 2022():6820377. PubMed ID: 36474714
[TBL] [Abstract][Full Text] [Related]
3. Glucagon-Like Peptide-1 Receptor Agonists and Cardiovascular Risk Reduction in Type 2 Diabetes Mellitus: Is It a Class Effect?
Li Y; Rosenblit PD
Curr Cardiol Rep; 2018 Sep; 20(11):113. PubMed ID: 30259238
[TBL] [Abstract][Full Text] [Related]
4. Cardiovascular effects of incretins: focus on glucagon-like peptide-1 receptor agonists.
Madsbad S; Holst JJ
Cardiovasc Res; 2023 May; 119(4):886-904. PubMed ID: 35925683
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness and Tolerability of Once-Weekly GLP-1 Receptor Agonists in Clinical Practice: A Focus on Switching Between Once-Weekly Molecules in Type 2 Diabetes.
Di Dalmazi G; Coluzzi S; Baldassarre MPA; Ghit A; Graziano G; Rossi MC; Ciappini B; Milo M; Carrieri F; Nicolucci A; Consoli A; Formoso G
Front Endocrinol (Lausanne); 2022; 13():892702. PubMed ID: 35909534
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists on Body Weight and Cardiometabolic Parameters in Individuals With Obesity and Without Diabetes: A Systematic Review and Meta-Analysis.
Ansari HUH; Qazi SU; Sajid F; Altaf Z; Ghazanfar S; Naveed N; Ashfaq AS; Siddiqui AH; Iqbal H; Qazi S
Endocr Pract; 2024 Feb; 30(2):160-171. PubMed ID: 38029929
[TBL] [Abstract][Full Text] [Related]
7. Semaglutide: The Newest Once-Weekly GLP-1 RA for Type 2 Diabetes.
Tuchscherer RM; Thompson AM; Trujillo JM
Ann Pharmacother; 2018 Dec; 52(12):1224-1232. PubMed ID: 29932006
[TBL] [Abstract][Full Text] [Related]
8. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art.
Nauck MA; Quast DR; Wefers J; Meier JJ
Mol Metab; 2021 Apr; 46():101102. PubMed ID: 33068776
[TBL] [Abstract][Full Text] [Related]
9. Decision Algorithm for Prescribing SGLT2 Inhibitors and GLP-1 Receptor Agonists for Diabetic Kidney Disease.
Li J; Albajrami O; Zhuo M; Hawley CE; Paik JM
Clin J Am Soc Nephrol; 2020 Nov; 15(11):1678-1688. PubMed ID: 32518100
[TBL] [Abstract][Full Text] [Related]
10. Glucagon-Like Peptide-1 Receptor Agonists in the Treatment of Obesity.
Jensterle M; Janež A
Horm Res Paediatr; 2023; 96(6):599-608. PubMed ID: 34852347
[TBL] [Abstract][Full Text] [Related]
11. Glucagon-like Peptide-1 Receptor Agonists versus Sodium-Glucose Cotransporter Inhibitors for Treatment of T2DM.
McKee A; Al-Khazaali A; Albert SG
J Endocr Soc; 2020 May; 4(5):bvaa037. PubMed ID: 32342023
[TBL] [Abstract][Full Text] [Related]
12. Healthcare professionals' perceptions and management of obesity & knowledge of glucagon, GLP-1, GIP receptor agonists, and dual agonists.
Garvey WT; Mahle CD; Bell T; Kushner RF
Obes Sci Pract; 2024 Jun; 10(3):e756. PubMed ID: 38708040
[TBL] [Abstract][Full Text] [Related]
13. Cardiovascular safety outcomes of once-weekly GLP-1 receptor agonists in people with type 2 diabetes.
Goldman JD
J Clin Pharm Ther; 2020 Sep; 45 Suppl 1(Suppl 1):61-72. PubMed ID: 32910492
[TBL] [Abstract][Full Text] [Related]
14. Glucagon-Like Peptide-1 Receptor Agonist Use in People Living with Type 2 Diabetes Mellitus and Chronic Kidney Disease: A Narrative Review of the Key Evidence with Practical Considerations.
Górriz JL; Romera I; Cobo A; O'Brien PD; Merino-Torres JF
Diabetes Ther; 2022 Mar; 13(3):389-421. PubMed ID: 35175551
[TBL] [Abstract][Full Text] [Related]
15. A Peptide in a Pill - Oral Semaglutide in the Management of Type 2 Diabetes.
Selvarajan R; Subramanian R
Diabetes Metab Syndr Obes; 2023; 16():1709-1720. PubMed ID: 37312901
[TBL] [Abstract][Full Text] [Related]
16. Oral GLP1 Analog: Where Does the Tide Go?
Gardner H; Hamdy O
Clin Med Insights Endocrinol Diabetes; 2020; 13():1179551420984130. PubMed ID: 33447122
[TBL] [Abstract][Full Text] [Related]
17. Cardiovascular Outcomes with Once-Weekly GLP-1 RAs: Clinical and Economic Implications.
Heile M; Wyne K; Billings LK; Cannon A; Handelsman Y; Shannon M
J Manag Care Spec Pharm; 2018 Sep; 24(9-a Suppl):S42-S52. PubMed ID: 30156446
[TBL] [Abstract][Full Text] [Related]
18. Effects of finerenone and glucagon-like peptide 1 receptor agonists on cardiovascular and renal outcomes in type 2 diabetes mellitus: a systematic review and meta-analysis.
Gu X; Jiang S; Yang Y; Li W
Diabetol Metab Syndr; 2024 Jan; 16(1):14. PubMed ID: 38212831
[TBL] [Abstract][Full Text] [Related]
19. Association Between the Magnitude of Glycemic Control and Body Weight Loss With GLP-1 Receptor Agonists and Risk of Atherosclerotic Cardiovascular Disease: A Systematic Review and Meta-analyses of Randomized Diabetes Cardiovascular Outcomes Trials.
Gomes DA; Presume J; de Araújo Gonçalves P; Almeida MS; Mendes M; Ferreira J
Cardiovasc Drugs Ther; 2024 Jan; ():. PubMed ID: 38214869
[TBL] [Abstract][Full Text] [Related]
20. Impact of a pharmacist-led weight management service in a cardiology clinic.
Yates M; Supple M; Maccia M
J Am Pharm Assoc (2003); 2024; 64(2):557-563. PubMed ID: 37944862
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
